Nautilus Biotechnology (NAUT) Amortization of Deferred Charges (2020 - 2026)

Nautilus Biotechnology (NAUT) has 7 years of Amortization of Deferred Charges data on file, last reported at $1.1 million in Q1 2026.

• For the quarter ending Q1 2026, Amortization of Deferred Charges fell 1.55% year-over-year to $1.1 million; the trailing twelve-month figure through Mar 2026 stood at $7.7 million (up 72.78% YoY), and the FY2025 full-year result was $4.7 million, up 7.63% from the prior year.
• Amortization of Deferred Charges slipped to $1.1 million in Q1 2026, from $4.2 million in the prior quarter.
• In the past five years, Amortization of Deferred Charges ranged from a high of $4.2 million in Q4 2025 to a low of $525000.0 in Q1 2022.
• A 5-year average of $1.1 million and a median of $1.1 million in 2024 frame the typical range for Amortization of Deferred Charges.
• Across the five-year window, Amortization of Deferred Charges decreased 5.12% in 2022 and surged 274.67% in 2025, its largest moves.
• Tracing NAUT's Amortization of Deferred Charges over 5 years: stood at $575000.0 in 2022, then soared by 80.0% to $1.0 million in 2023, then climbed by 8.31% to $1.1 million in 2024, then surged by 274.67% to $4.2 million in 2025, then slumped by 72.81% to $1.1 million in 2026.
• Business Quant data shows NAUT's Amortization of Deferred Charges at $1.1 million in Q1 2026, $4.2 million in Q4 2025, and $1.2 million in Q3 2025.